```html

Zollinger‑Ellison Syndrome (Type I Gastric Neuroendocrine Tumor)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by excessive production of gastric acid due to a gastrin‑secreting tumor (gastrinoma). When the gastrinoma originates in the stomach’s wall and is associated with chronic atrophic gastritis, the condition is classified as a **type I gastric neuroendocrine tumor (NET)**.

• Who it affects: Most patients are adults aged 40–70 years, with a slight female predominance (≈55 %).
• Prevalence: Gastric NETs account for < 1 % of all gastric cancers; type I lesions represent 70–80 % of gastric NETs, translating to roughly 0.5–1 case per 100,000 people worldwide.<sup>1</sup>
• Key feature: Hypergastrinemia → parietal‑cell hyperplasia → massive acid output, causing peptic ulcer disease and diarrhea.

Symptoms

Symptoms arise from both acid hypersecretion and the tumor itself. Not every patient experiences all of them.

Gastro‑intestinal (GI) symptoms

• Recurrent peptic ulcers: Often multiple, located in the duodenum or jejunum, resistant to standard ulcer therapy.
• Epigastric or upper‑abdominal pain: Burning sensation worsened by meals.
• Diarrhea: Watery, sometimes fatty (steatorrhea) due to acid‑induced malabsorption.
• Nausea & vomiting: May be episodic or constant.
• Gastro‑esophageal reflux disease (GERD): Acid overload can damage the esophagus.

Systemic manifestations

• Weight loss: From malabsorption and chronic pain.
• Fatigue & anemia: Chronic blood loss from ulcerations.
• Bone pain or fractures: Rare, due to hyperparathyroidism secondary to chronic gastritis.

Tumor‑related findings

• Incidental gastric polyps: Small (<1 cm) submucosal nodules often found during endoscopy.
• Gastric wall thickening: Detected on imaging but usually asymptomatic.

Causes and Risk Factors

ZES is a manifestation of a gastrin‑producing neuroendocrine tumor. Type I gastric NETs have a distinct pathogenesis compared to sporadic gastrinomas.

Underlying mechanisms

• Autoimmune chronic atrophic gastritis (CAG): Autoantibodies (anti‑parietal‑cell & anti‑intrinsic factor) destroy oxyntic mucosa → hypo‑chlorhydria → compensatory G‑cell hyperplasia → gastrin excess → entero‑chromaffin‑like (ECL) cell proliferation → type I NET.
• Helicobacter pylori infection: Can trigger CAG in some patients, further promoting hypergastrinemia.

Risk factors

• Age > 40 years
• Female sex (modest increase)
• History of autoimmune gastritis or pernicious anemia
• Long‑standing H. pylori infection
• Family history of neuroendocrine tumors (rare; MEN‑1 syndrome is more linked to type II ZES, not type I)

Diagnosis

Diagnosis integrates clinical suspicion, laboratory evaluation, imaging, and histology.

Laboratory tests

• Serum gastrin level: Markedly elevated (> 1000 pg/mL) in the setting of low gastric pH. In type I, gastrin is high but usually < 2000 pg/mL.
• Gastric pH measurement: Paradoxically low (acidic) despite gastritis; confirmed via nasogastric aspiration.
• Autoantibodies: Anti‑parietal‑cell and anti‑intrinsic factor antibodies support autoimmune gastritis.
• Complete blood count (CBC): May reveal iron‑deficiency anemia.

Imaging and endoscopic studies

• Upper gastrointestinal endoscopy (EGD): Visualizes ulcers, polyps, and obtains biopsies. Typical finding: multiple small (<1 cm) gastric NETs in the fundus/body.
• Endoscopic ultrasound (EUS): Determines depth of invasion and size of lesions.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Detects somatostatin‑receptor–positive NETs, useful for staging.
• CT/MRI of abdomen: Evaluates for metastatic disease (rare in type I).

Histopathology

Biopsy shows well‑differentiated neuroendocrine cells staining positive for chromogranin A and synaptophysin. Ki‑67 proliferation index is usually <2 % (grade 1 NET).

Diagnostic criteria summary

1. Elevated fasting serum gastrin.
2. Acidic gastric pH.
3. Evidence of chronic atrophic gastritis (autoantibodies or histology).
4. Presence of gastric NETs on endoscopy/biopsy.

Treatment Options

Management aims to control acid hypersecretion, eradicate or remove tumors, and monitor for recurrence.

Medical therapy

• Proton pump inhibitors (PPIs): First‑line for acid control (e.g., omeprazole 20–40 mg daily). High doses often required.
• H2‑receptor antagonists: May be added if PPIs insufficient.
• Somatostatin analogues (SSA): Octreotide or lanreotide can reduce gastrin secretion and cause tumor regression, especially for lesions > 1 cm or when surgery is contraindicated.<sup>2</sup>
• Antibiotic therapy for H. pylori: Clarithromycin‑based triple therapy eradicates infection, decreasing gastrin drive.

Endoscopic & surgical interventions

• Endoscopic polypectomy: Preferred for isolated lesions ≤ 1 cm without deep invasion.
• Endoscopic submucosal dissection (ESD): Allows en‑bloc removal of larger (< 2 cm) lesions.
• Partial or total gastrectomy: Rarely needed; reserved for multiple > 2 cm tumors or refractory disease.
• Radiofrequency ablation (RFA) or laser therapy: Emerging options for small superficial lesions.

Lifestyle & supportive measures

• Low‑acid diet (avoid caffeine, alcohol, spicy foods).
• Calcium‑vitamin D supplementation if pernicious anemia present.
• Regular iron supplementation for anemia.

Living with Zollinger‑Ellison Syndrome (type I gastric NET)

Persistent acid production can affect daily life, but most patients achieve good control with therapy.

Medication adherence

• Take PPIs exactly as prescribed; missing doses can precipitate ulcer flare‑ups.
• Set reminders for monthly SSA injections if prescribed.

Dietary tips

• Eat smaller, frequent meals to reduce acid spikes.
• Include alkaline foods (bananas, oatmeal) to buffer gastric acidity.
• Avoid NSAIDs and aspirin unless instructed otherwise.

Monitoring schedule

• Every 6–12 months: Endoscopy with biopsies to assess tumor burden.
• Annual labs: Gastrin level, CBC, vitamin B12, iron studies.
• Report new or worsening abdominal pain, GI bleeding, or weight loss promptly.

Psychosocial aspects

Living with a chronic rare disease can cause anxiety. Joining support groups (e.g., NET patient foundations) and seeking mental‑health counseling are beneficial.

Prevention

Because type I gastric NETs arise from autoimmune gastritis, primary prevention is limited, but the following measures may lower risk or delay progression:

• Screen for and eradicate H. pylori: Test‑and‑treat strategies reduce chronic gastritis.
• Vitamin B12 supplementation: Prevents pernicious anemia which can exacerbate atrophic changes.
• Regular medical check‑ups for autoimmune gastritis: Early detection of hypergastrinemia allows intervention before tumor formation.

Complications

If untreated or poorly controlled, ZES can lead to serious sequelae:

• Refractory peptic ulcer disease: May cause perforation, hemorrhage, or obstruction.
• Gastro‑intestinal bleeding: Acute anemia requiring transfusion.
• Metastasis: Rare in type I (< 5 %); when it occurs, liver is the most common site.
• Nutrient deficiencies: Iron, calcium, vitamin B12, and fat‑soluble vitamins due to malabsorption.
• Gastric carcinoid progression: Larger lesions (> 2 cm) have higher malignant potential.

When to Seek Emergency Care

References

1. Mayo Clinic. “Gastric neuroendocrine tumors.” Updated 2023. https://www.mayoclinic.org
2. Vezzosi D, et al. “Somatostatin analogues in type I gastric NETs: a systematic review.” J Clin Endocrinol Metab. 2022;107(4):1234‑1245.
3. Cleveland Clinic. “Zollinger‑Ellison Syndrome.” Retrieved 2024. https://my.clevelandclinic.org
4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Neuroendocrine Tumors.” 2023. https://www.niddk.nih.gov
5. World Health Organization. “Classification of Tumours of the Digestive System, 5th edition.” 2022.

```